Page 158 - Read Online

Kumar et al. Cancer Drug Resist 2019;2:161-77 I http://dx.doi.org/10.20517/cdr.2018.27 Page 173

9. Giancotti FG. Deregulation of cell signaling in cancer. FEBS lett 2014;588:2558-70.
10. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer
Cell Int 2005;5:1-13.
11. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
Cancer Control 2003;10:159-65.
12. Triller N, Korošec P, Kern I, Košnik M, Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein,
multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006;54:235-
40.
13. Nooter K, De La Riviere GB, Look MP, Van Wingerden KE, Henzen-Logmans SC, et al. The prognostic significance of expression of
the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997;76:486-93.
14. Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, et al. MRP1 not MDR1 gene expression is the predominant mechanism of acquired
multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 2000;3:66-75.
15. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells.
Proc Natl Acad Sci U S A 1998;95:15665-70.
16. Robey RW, Shukla S, Steadman K, Obrzut T, Finley EM, et al. Inhibition of ABCG2-mediated transport by protein kinase inhibitors
with a bisindolylmaleimide or indolocarbazole structure. Mol Cancer Ther 2007;6:1877-85.
17. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist
Updat 2012;15:70-80.
18. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in
patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005;104:682-91.
19. Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, et al. A randomized, placebo-controlled, double-blind phase 2 study of
docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have
received one prior chemotherapy regimen. Cancer Chemother Pharmacol 2009;64:763-8.
20. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, et al. Relationship of cellular glutathione to the cytotoxicity and
resistance of seven platinum compounds. Cancer Res 1992;52:6885-9.
21. Schwartz PM, Moir RD, Hyde CM, Turek PJ, Handschumacher RE. Role of uridine phosphorylase in the anabolism of 5-fluorouracil.
Biochem Pharmacol 1985;34:3585-9.
22. Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma.
Eur J Cancer Clin Oncol 1983;19:807-15.
23. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist
2002;7:288-323.
24. Kosuri KV, Wu X, Wang L, Villalona-Calero MA, Otterson GA. An epigenetic mechanism for capecitabine resistance in mesothelioma.
Biochem Biophys Res Commun 2010;391:1465-70.
25. Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA
methylation in colon cancer cells. BMC Mol Biol 2010;11:1-11.
26. Toffoli G, Cecchin E, Gasparini G, D’Andrea M, Azzarello G, et al. Genotype-driven phase I study of irinotecan administered in
combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:866-71.
27. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001;186:153-68.
28. Oshimori N, Oristian D, Fuchs E. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 2015;160:963-76.
29. Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine
erythropoiesis, growth, and development. Proc Natl Acad Sci U S A 1996;93:13943-8.
30. Jung BJ, Yoo HS, Shin S, Park YJ, Jeon SM. Dysregulation of NRF2 in cancer: from molecular mechanisms to therapeutic
opportunities. Biomol Ther 2018;26:57-68.
31. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and
mammals. Proc Natl Acad Sci U S A 2002;99:14298-302.
32. Yee SW, Gong L, Badagnani I, Giacomini KM, Klein TE, et al. SLC19A1 pharmacogenomics summary. Pharmacogenet Genomics
2010;20:708-15.
33. Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010;2:293-301.
34. Morales C, García MJ, Ribas M, Miró R, Muñoz M, et al. Dihydrofolate reductase amplification and sensitization to methotrexate of
methotrexate-resistant colon cancer cells. Mol Cancer Ther 2009;8:424-32.
35. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008;6:1-8.
36. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, et al. ABCC2 (MRP2, cMOAT) can be localized in
the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res
2006;12:7149-58.
37. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in
breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014; 5:4603-50.
38. Barouch-Bentov R, Sauer K. Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs 2011;20:153-208.
39. Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-
induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731-45.
40. Sun Y, Campisi J, Higano C, Beer TM, Porter P, et al. Treatment-induced damage to the tumor microenvironment promotes prostate